Vmn2r52 Inhibitors
Vmn2r52 function primarily by targeting various signaling pathways that are essential for the activation and regulation of this protein. Olmutinib, as a selective inhibitor of EGFR, can impede the activation of downstream pathways, notably the MAPK/ERK pathway, which is a central conduit for signaling cascades that can affect the activity of Vmn2r52. Similarly, erlotinib and gefitinib, which also target EGFR, can suppress downstream ERK signaling, thereby reducing the signaling environment conducive to Vmn2r52 activity. Sorafenib extends this inhibition by targeting not just one but several receptors and kinases that participate in the MAPK/ERK pathway, as well as other pathways, leading to a broad reduction in signaling potential. Vandetanib's multi-receptor target approach also diminishes the signaling that might otherwise influence Vmn2r52.
Vmn2r52 can be indirectly attenuated by compounds that target key regulatory enzymes within the cell cycle and downstream signaling pathways. Palbociclib, by inhibiting CDK4/6, can decrease the proliferation of cells that express Vmn2r52, leading to a reduced functional presence of the protein. GW5074 and U0126 take aim at the MAPK/ERK pathway by inhibiting c-Raf and MEK, respectively, which are critical for the phosphorylation and subsequent activation of ERK. The MEK inhibitors trametinib, PD0325901, and AZD6244 (Selumetinib) further emphasize this point of attack, ensuring a diminution of the ERK pathway's influence on Vmn2r52. Lenvatinib, by inhibiting multiple tyrosine kinases, including VEGFR, FGFR, and PDGFR, can potentially alter the signaling milieu that supports the functional state of Vmn2r52. Collectively, these chemical inhibitors manage to suppress the various signaling mechanisms that can foster the activity of Vmn2r52, albeit through different but complementary modes of action.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of CDK4/6, which are critical for cell cycle progression. By inhibiting these kinases, palbociclib may decrease the proliferation of cells expressing Vmn2r52, thereby indirectly reducing the functional expression of this protein by limiting the number of cells that express it. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases such as VEGFR and PDGFR, as well as downstream kinases in the RAS/RAF/MEK/ERK pathway. Inhibition of this pathway can reduce the signaling potential of cells expressing Vmn2r52, which may depend on this pathway for certain aspects of its function. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of c-Raf kinase, which is part of the MAPK/ERK pathway. By inhibiting c-Raf, GW5074 can suppress the downstream signaling that might contribute to the functional activity of Vmn2r52. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that prevents the activation of MAPK/ERK pathway. Given that Vmn2r52 may rely on the MAPK/ERK pathway for some of its functions, trametinib can indirectly inhibit the actions of Vmn2r52 by suppressing this pathway. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib is a multi-targeted tyrosine kinase inhibitor affecting VEGFR, FGFR, PDGFR, and others. Although Vmn2r52 is not directly tied to these receptors, the broad inhibition of growth factor signaling can indirectly reduce the signaling environment that supports Vmn2r52 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, which are upstream activators of ERK1/2 in the MAPK/ERK pathway. By inhibiting MEK, U0126 can diminish the downstream signaling that may be necessary for the proper functioning of Vmn2r52. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a tyrosine kinase inhibitor that targets VEGFR, EGFR, and RET. By inhibiting these pathways, it may decrease the downstream signaling that influences the functional capabilities of Vmn2r52. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that can reduce the activation of downstream pathways such as MAPK/ERK. By doing so, it may indirectly inhibit the functional activity of Vmn2r52, which could be affected by changes in these pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor that could decrease downstream signaling through the MAPK/ERK pathway. This reduction in signaling has the potential to indirectly inhibit the functional activity of Vmn2r52. | ||||||